In this issue:
Rituximab vs. dimethyl fumarate in RR-MS & CIS
Long-term disability outcomes in low- & high-efficacy DMTs
MS severity, latitude, age & UVB exposure
Sex differences in MS severity
68-year epidemiological MS changes in Hobart, Tasmania
sNfL levels as a biomarker of future disability in progressive MS
NEDA-3 rates in the CLARITY Extension study
Rate of relapse after cessation of DMT in RR-MS
Serum IgM-PC as a biomarker of response to natalizumab & interferon-β
Relapse rates in transitions between S1Ps & anti-CD20s
Please login below to download this issue (PDF)